Concepedia

Author

J. Alexandre

Université Paris Cité

Also Known As

C. Abdeddaim, J Alexandre, J. Alexandre, J. H. Alexandre, Jean-Michel Alexandre, João Ricardo Signoretti Alexandre

86

Publications

1.2K

Citations

20

H-Index

51

Concepts

All Affiliations

Université Paris CitéAssistance Publique – Hôpitaux de ParisDélégation Paris 5Hôpital CochinInstitut Gustave Roussy
JA

About

J. Alexandre is an author at Université Paris Cité specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

13

14

706

2

Health Sciences

2

2

140

3

Natural Sciences

1

1

21

4

Biochemistry

1

1

21

5

Cell Biology

1

1

21

J. Alexandre

×

22

Publications

955

Citations

18

H-Index

YearCitations

Evaluation of the nutritional and inflammatory status in cancer patients for the risk assessment of severe haematological toxicity following chemotherapy

J. Alexandre, M. Gross-Goupil, Bruno Falissard,

Annals of Oncology

2002

130

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)

Alain Lortholary, R. Largillier, B. Weber,

Annals of Oncology

2011

92

Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity

Olivier Mir, J. Alexandre, A. Tran,

Annals of Oncology

2009

84

Stage I non-seminomatous germ-cell tumours of the testis

J. Alexandre, Karim Fizazi, C Mahé,

European Journal of Cancer

2001

75

Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study

J. Alexandre, Elisabeth Rey, V. Girre,

Annals of Oncology

2006

64

Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients

Edith Carton, Gaëlle Noé, Olivier Huillard,

European Journal of Cancer

2016

63

Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients

Céline Narjoz, Anatole Cessot, Audrey Thomas‐Schoemann,

Investigational New Drugs

2014

50

Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer

Andrés Poveda, J.M. del Campo, Isabelle Ray‐Coquard,

Annals of Oncology

2017

46

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

J. Alexandre, Chris Brown, David Coeffic,

British Journal of Cancer

2012

44

Phase I/II dose-finding, safety and efficacy study of radium-223 dichloride in renal cell carcinoma patients with bone metastases

Réza Elaidi, Yann Vano, Nicolas Aide,

Annals of Oncology

2016

44

Page 1